Skip to main content
Premium Trial:

Request an Annual Quote

Itus, Wistar Institute Renew Agreement to Develop Cancer Detection Platform

NEW YORK (360Dx) – Itus said today it has renewed a collaborative agreement with the Wistar Institute for the development of its Cchek early cancer detection technology.

Itus is developing the Cchek platform through Anixa Diagnostics, its subsidiary. The platform is a series of non-invasive blood tests for the early detection of solid tumor cancers based on the body's immunological response to malignancy.

Itus Chairman and CEO Amit Kumar said in a statement, "Wistar's R&D support has been and continues to be valuable to the development of Cchek."

Itus is using artificial intelligence and flow-cytometry analysis of immune cells from an individual's blood to identify patients with tumors.

"As we are monitoring subtle changes in [the] immune response of individuals, we expect this technology to be able to identify patients bearing any type of tumor," he said.

The firm said it has demonstrated the efficacy of its technology in identifying 15 different types of tumors. It is deciding on which tumor types would provide the focus for its first commercial effort.